title: Enhanced biological activity of human recombinant interleukin 2 coupled to mouse red blood cells as evaluated using the mouse Meth A sarcoma model.
abstract: In order to circumvent the toxicity associated with high-dose interleukin 2 (IL2) administration and its rapid clearance from the circulation, a carrier system for IL2 is needed. Red blood cells (RBCs) coated with recombinant interleukin 2 (rIL2) provide a means of delivering IL2 into the system in a continuous low-dose manner which, in turn, maintains a low, potentially non-toxic, IL2 concentration. Murine RBCs coated with rIL2 (RBCs-rIL2) are able to induce cytotoxic activity in mouse spleen cells in vitro against malignant murine YAC-1 cells (53-62% cytotoxicity) using less than 4500 i.u./10(9) RBCs per mouse. Cytotoxicity (21-31%) becomes apparent upon cytotoxic testing of spleens cells stimulated in vivo. Using the murine Meth A sarcoma model, the effectiveness of this RBC-rIL2 vehicle is demonstrated in vivo by a 84% reduction in tumour size as compared with the soluble-rIL2-treated mice. Moreover, the RBC-rIL2 vehicle is able to induce tumoricidal cytotoxicity with very low rIL2 concentrations (about 10,000 i.u. of rIL2/mouse). These results indicate that rIL2 retains its biological activity when bound to the RBC and therefore could prove useful as a therapeutic delivery system for cancer treatment.
authors.affiliation: Food Animal Protection Research Laboratory, Agricultural Research Service, U.S. Department of Agriculture, College Station, TX 77845, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Moyes
authors.forename: H
authors.initials: H
authors.lastname: Kirch
authors.forename: J R
authors.initials: JR
authors.lastname: DeLoach
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood / Q000627:therapeutic use*; D002860:Chromium Radioisotopes; D016207:Cytokines / Q000096:biosynthesis; D003602:Cytotoxicity, Immunologic; D004912:Erythrocytes / Q000737:chemistry*; D005069:Evaluation Studies as Topic; D005354:Fibrosarcoma / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007376:Interleukin-2 / Q000097:blood / Q000627:therapeutic use*; D008748:Methylcholanthrene; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000097:blood / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D002860:Chromium Radioisotopes; D016207:Cytokines; D007376:Interleukin-2; D011994:Recombinant Proteins; D008748:Methylcholanthrene; D007371:Interferon-gamma